ABL Income Statement - Abbott Laboratories

Watchlist Manager

Watchlist

Price: 88.5 EUR -3.01% Market Closed

Market Cap: €154B

A	Abbott Laboratories XMUN:ABL	US
	American Express Co NYSE:AXP	US
F	Flywire Corp F:9E2	US
I	Ingredion Inc XMUN:CNP	US
C	Coherent Corp LSE:0LHO	US
	Siemens Energy AG F:ENR	DE
	Blackstone Inc NYSE:BX	US
R	Renault SA XMUN:RNL	FR

Financial profile · Q2 FY2026

A diversified healthcare portfolio with durable cash generation and moderate operating leverage

Abbott’s multi-year history shows a diversified healthcare model combining moderate sales expansion with resilient operating margins and recurring positive free cash flow. Capital spending generally remains below operating cash generation, allowing internally generated cash to fund dividends, repurchases, and acquisitions.

What changed

The latest period marks an inflection in financing and business mix: Exact Sciences added a diagnostics platform but also introduced acquisition-related amortization, integration costs, and debt interest. Operating cash flow and free cash flow remained positive, so the shift is toward a more leveraged integration phase rather than a breakdown in cash generation.

What matters next

Whether post-acquisition operating cash flow continues to cover capital spending, dividends, and the higher interest burden without sustained new borrowing.

Metric	FY2016 Dec 2016	FY2017 Dec 2017	FY2018 Dec 2018	FY2019 Dec 2019	FY2020 Dec 2020	FY2021 Dec 2021	FY2022 Dec 2022	FY2023 Dec 2023	FY2024 Dec 2024	FY2025 Dec 2025
Revenue	20.9B	27.4B	30.6B	31.9B	34.6B	43.1B	43.7B	40.1B	42B	44.3B
Cost of Revenue	(9.1B)	(12.4B)	(12.7B)	(13.2B)	(15B)	(18.5B)	(19.1B)	(17.9B)	(18.6B)	(19.2B)
Gross Profit	11.8B	15B	17.9B	18.7B	19.6B	24.6B	24.6B	22.2B	23.3B	25.1B
Operating Expenses	(8.7B)	(13.1B)	(14.2B)	(14B)	(14.2B)	(16B)	(15.9B)	(15.5B)	(16.3B)	(16.8B)
Selling, General & Administrative	(6.7B)	(9B)	(9.7B)	(9.7B)	(9.7B)	(11.2B)	(11.1B)	(10.9B)	(11.7B)	(12.2B)
R&D	(1.4B)	(2.2B)	(2.3B)	(2.4B)	(2.4B)	(2.7B)	(2.7B)	(2.6B)	(2.8B)	(2.9B)
Depreciation & Amortization	(550m)	(2B)	(2.2B)	(1.9B)	(2.1B)	(2B)	(2B)	(2B)	(1.9B)	(1.7B)
Operating Income	3.1B	1.9B	3.7B	4.7B	5.4B	8.6B	8.7B	6.7B	7B	8.3B
Net Interest Income (Expense)	(827m)	(746m)	(749m)	(583m)	(492m)	(491m)	(377m)	(293m)	(188m)	(135m)
Interest Expense	431m	904m	826m	670m	546m	533m	558m	637m	559m	493m
Non-Recurring Items	(32m)	(307m)	(247m)	(201m)	42m	(163m)	(390m)	(283m)	(350m)	(274m)
Total Other Income	(786m)	1.4B	139m	191m	(12m)	277m	366m	518m	558m	548m
Pre-Tax Income	1.4B	2.2B	2.9B	4.1B	5B	8.2B	8.3B	6.7B	7B	8.5B
Tax Provision	(350m)	(418m)	(409m)	(476m)	(471m)	(1.1B)	(1.4B)	(941m)	6.4B	(1.9B)
Income from Continuing Operations	1.1B	1.8B	2.5B	3.6B	4.5B	7.1B	6.9B	5.7B	13.4B	6.5B
Net Income	1.4B	477m	2.4B	3.7B	4.5B	7.1B	6.9B	5.7B	13.4B	6.5B
EPS (Diluted)	0.94	0.27	1.33	2.07	2.52	3.95	3.93	3.27	7.67	3.73